This is an automatically translated article.
Blenrep contains the monoclonal antibody Belantamab Mafodotin-blmf and is indicated in the treatment of certain cancers. However, Blenrep can lead to some serious side effects that should be taken with special care.
1. What are the uses of Blenrep?
Belantamab Mafodotin-blmf in Blenrep is a monoclonal antibody. Monoclonal antibodies are created in the laboratory to bind to targets found on specific types of cancer cells. Blenrep's effect is to trigger the immune system to attack the cell it attaches to, leading the immune system to destroy that cell.
Monoclonal antibodies can work in a variety of ways, including stimulating the immune system to kill cells, stopping cell growth, or inhibiting processes necessary for cell growth. cell. Belantamab Mafodotin-blmf in Blenrep is an antibody against B-cell maturation antigens.
Blenrep is indicated for the treatment of multiple myeloma (cancer of the bone marrow - a blood cancer affecting the cells of the bone marrow). plasma cells).
2. How to use Blenrep
Blenrep is an intravenous infusion drug. Dosage will depend on the patient's weight and the body's response to the drug with the frequency of use decided by the doctor. If there has been a reaction to Blenrep , the patient may be prescribed some anti - reaction drugs before Blenrep infusion .
3. Side effects of the drug Blenrep
3.1. Effects on the eyes Blenrep can cause a number of different problems with your eyes and vision. Patients will have their eyes checked before starting, during use, and when there are any sudden changes in vision as a result of taking Blenrep. Patients should notify their treating physician immediately if they begin to notice any changes in their vision, including loss of vision, blurred vision, or dry eyes. Blenrep can lead to other problems such as keratosis and corneal ulcers. Because of possible side effects, it is important for patients to follow any instructions given by the manufacturer or doctor to ensure eye health. Guidelines may include: frequent use of lubricating eye drops to keep moist or limit contact lens wear. Contact a doctor immediately if patient is having any new or worsening eye problems.
3.2. Decreased Platelet Count Platelets are an important part of the blood clotting system, so a low platelet count means a higher risk of bleeding. Patients should let Blenrep know if bruising or unusual bleeding occurs, including nosebleeds, bleeding gums, bloody urine, or melena. If the platelet count is too low, the patient may need a platelet transfusion to replenish it.
Some notes to reduce the risk of bleeding during treatment with Blenrep:
No/limit the use of razors; Limit or avoid playing contact sports and participating in activities that pose a risk of injury or bleeding; Concomitant use of Blenrep with Aspirin, steroids and non-steroidal anti-inflammatory drugs (NSAIDs) may increase the risk of bleeding. Please consult your doctor about the use of these products as well as all over-the-counter medications during treatment with Blenrep; Limit the use of dental floss or toothpicks; Use a soft-bristled toothbrush to clean your teeth. 3.3. Increased risk of infection White blood cells play a vital role in protecting the body from infection. During cancer treatment with Blenrep, a patient's white blood cell count may drop low and lead to a higher risk of infection. Patients should notify their doctor immediately if they develop symptoms of an infection such as fever (temperature over 38 degrees Celsius), sore throat, cold, shortness of breath, cough, painful urination, or slow-healing sores.
Some doctor's recommendations to prevent infection while taking Blenrep :
Wash your hands well, often; Limit going to crowded places or contact with patients with contagious diseases; When working in a specific environment, the sick person should wear protective clothing, including long pants and gloves; Do not dispose of pet waste in the home; Keep the wound or sore clean; Regular personal hygiene; Do not trim the corner of the nail or ingrown toenail; Consult a doctor before performing dental interventions; Contact your doctor if the patient or family member is about to be vaccinated. 3.4. Anemia Red blood cells play an important role in transporting oxygen to tissues in the body. When the red blood cell count is low, the patient often feels tired or weak. Patients taking Blenrep should notify their doctor if they experience rapid breathing, shortness of breath, or chest pain.
3.5. Hepatotoxicity Blenrep can negatively affect the liver, causing hepatotoxicity. Your doctor can monitor you by having the patient perform liver function tests. On the patient's part, it is necessary to inform the doctor if symptoms such as jaundice and/or yellow eyes, dark or brown urine, right upper quadrant abdominal pain... These symptoms may suggest toxic status. liver.
3.6. Hyperglycemia Blenrep may increase blood sugar in patients with or without diabetes. The doctor will have a plan to monitor the patient's blood sugar. If you have unusual symptoms such as excessive thirst, frequent urination, hunger, blurred vision, headache or fruity breath, notify your doctor as soon as possible. Patients with diabetes should closely monitor their own blood sugar and report the results to their doctor.
3.7. Kidney problems Blenrep may affect kidney function, including increasing blood creatinine levels, which your doctor can monitor using blood tests. Patients should notify their doctor if they notice a decrease in their daily urine output, hematuria, ankle swelling or loss of appetite.
3.8. Infusion-related Blenrep side effects The infusion of Blenrep may lead to a number of reactions such as chills, fever, flushing, shortness of breath, and increased blood pressure. Patients can take certain medications prior to infusion of Blenrep to prevent these reactions. Reactions due to Blenrep most commonly occur during the first few infusions. If the patient feels like he is having a reaction, tell the nurse right away.
3.9. Pneumonia Patients can develop pneumonia during cancer treatment with Blenrep . Notify the oncologist immediately if a patient develops any new or worsening symptoms, including rapid breathing, shortness of breath, cough, or fever.
Concerns about Blenrep's sexual reproductive effects:
The active ingredient in Blenrep may affect a person's reproductive function, leading to menstrual cycle disturbances in women or decreased sperm production in men. . Women may experience the effects of menopause including hot flashes and vaginal dryness. In addition, libido may decrease during treatment with Blenrep; Patients can consider sperm or egg banks if they want to have children in the future; Exposure of the fetus to Blenrep can cause birth defects, so patients should not become pregnant while taking Blenrep. Use of effective birth control is essential during treatment and for at least 4 months after treatment for women and 6 months for men, even if the menstrual cycle has stopped. stopped or there is evidence that the patient is not producing sperm; Patients should not breast-feed while taking Blenrep or for at least 3 months after the last dose. Blenrep contains the monoclonal antibody Belantamab Mafodotin-blmf and is indicated in the treatment of certain cancers.
Follow Vinmec International General Hospital website to get more health, nutrition and beauty information to protect the health of yourself and your loved ones in your family.
Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.
Reference source: .oncolink.org
